Screener
MiMedx Group MDXG Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by MiMedx Group in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: MiMedx Group’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001376339-26-000071
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Stock repurchased for tax withholdings on vesting of restricted stock | (2,028) | (2,984) |
| Principal payments on Citizens Term Loan Facility | (750) | (500) |
| Cash paid for Profit Share Payment (Note 12) | (607) | (488) |
| Deferred financing cost | (16) | — |
| Net cash flows used in financing activities | (15,869) | (3,972) |
| Net change in cash | (30,282) | 14,453 |
| Cash and cash equivalents, beginning of period | 166,121 | 104,416 |
| Cash and cash equivalents, end of period | $135,839 | $118,869 |
Item 1. Financial Statements
FAQ
- What is MiMedx Group's cash & equivalents?
- MiMedx Group (MDXG) reported cash & equivalents of $135.84M in Q2 2026.
- How has MiMedx Group's cash & equivalents changed year-over-year?
- MiMedx Group's cash & equivalents increased by 14.3% year-over-year, from $118.87M to $135.84M.
- What is the long-term trend for MiMedx Group's cash & equivalents?
- Over 5 years (2020 to 2025), MiMedx Group's cash & equivalents has grown at a 11.6% compound annual growth rate (CAGR), from $95.81M to $166.12M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about MiMedx Group's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude